Gland Pharma receives approval for Latanoprost Opthalmic Solution, 0.005%
The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Xalatan
The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Xalatan
WINREVAIR met primary endpoint of time to first morbidity or mortality event for the treatment of patients with pulmonary arterial hypertension (PAH) functional class III or IV at high risk of mortality
Performed within GENEWIZ from Azenta Life Sciences' CLIA-certified and CAP-accredited state-of-the-art clinical genomics laboratory
Aromatic L-amino acid decarboxylase deficiency is a rare genetic disorder that affects the production of some neurotransmitters
This agreement reinforces Lubrizol’s commitment to Make-In-India and broadens a previously committed US$ 350 million investment to support local manufacturing
Combined capabilities to drive novel healthcare applications presented at MEDICA 2024
The group plans to establish new hospitals in Kerala developing large health cities in Kochi and Kozhikode
The recognition from Malaysia's NPRA, a member of PIC/S, opens doors to new global business opportunities
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
Subscribe To Our Newsletter & Stay Updated